KP1, a laboratory-made fragment of Klotho, a protein whose levels fall with age, is studied to slow tissue scarring and sold only as a laboratory chemical. Mouse studies, nearly all from one research network, show it blocks the main scarring signal. No person has been documented to receive it, and no safety record or established dose exists. Risks are borrowed: skin tumors with another agent blocking that signal; contaminated supply. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Serum phosphorus | 2.5–4.5 mg/dL | Safety check: low phosphate with elevated Klotho |
| Serum calcium | 8.6–10.2 mg/dL | Safety check: same mineral disturbance |
| Intact parathyroid hormone (PTH) | 15–65 pg/mL | Safety check: overactive parathyroid with elevated Klotho |
| Estimated glomerular filtration rate (eGFR) | Not specified in the ER | Safety check: peptides clear through the kidney |
| Serum α-Klotho | Not specified in the ER | Expected to change: proposed indirect mechanism |
Cadence: No established cadence; absent data, a reasonable schedule repeats the chemistry panel at four and twelve weeks, then every three to six months, with the skin examination annually or immediately on any new lesion.